Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Quantum Pharma announces major contract

21st Sep 2015 07:00

RNS Number : 5918Z
Quantum Pharma PLC
21 September 2015
 

 

 

 

Press Release

 21 September 2015

 

 

Quantum Pharma Plc

("Quantum" or the "Group")

 

Quantum Pharma announces major Biodose® Services contract

 

Quantum Pharma Plc (AIM: QP.), the growing service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce the first large-scale NHS homecare contract win for its Biodose Services division. Following a competitive tender process, Biodose Services have been awarded an 18 month contract with Yorkshire and Humber NHS Pharmaceutical Purchasing Consortium ("YHPPC"), with an option to extend for a further two years by mutual consent.

Biodose Services provides pre-prepared medication regimes to care homes and delivery of medication to the home. This contract is to supply nearly 3,000 patients with medicines including antiretrovirals, anti-tuberculosis medication, medicines for cystic fibrosis, and oral chemotherapy medication, which will require 9,500 deliveries to individuals per annum. Biodose Services' expects to commence delivery in Q4 of 2015, and will reach full capacity within six months.

This contract marks a continuation of the progress seen by Biodose Services in the last year, following a contract agreed in June 2015 with The Newcastle upon Tyne Hospitals NHS Foundation Trust to supply arthritis medication to a number of patients, as well as operating the Stork Facility Service, providing homecare services to 1,200 patients (both private and NHS) per month.

 

The Group expects this contract to significantly increase turnover within the Biodose Services division, and make a modest contribution to group profitability, for the financial year ending 31 January 2017.

 

Andrew Scaife, Chief Executive Officer of Quantum Pharma Plc, said: "This contract shows the strength of the Biodose Services offering, which along with our Biodose® devices, aims to not only reduce the burden placed on the NHS by medication non-compliance, but also, allow patients to remain within a familiar environment, rather than spending unnecessary time in hospital. This contract provides an excellent platform to drive further penetration of Biodose®, and in-time Biodose Connect® (our telehealth product), as well as to identify further niche medicines to add to our growing development pipeline. I am pleased by the progress shown by Biodose Services within the last year and look forward to working with the Yorkshire and Humber NHS Pharmaceutical Purchasing Consortium to explore further opportunities across our business units." 

 

- Ends -

 

 

For further information:

Quantum Pharma Plc

 

Andrew Scaife, Chief Executive Officer

Tel: +44 (0) 1207 279 404

Martin Such, Chief Financial Officer

www.quantumpharmaplc.com

 

Zeus Capital Limited

(Nominated Adviser & Broker)

 

 

 

Andrew Jones / Nick Cowles / Jamie Peel

Tel: +44 (0) 16 1831 1512

Dominic Wilson / John Goold

Tel: +44 (0) 20 7533 7727

 

www.zeuscapital.co.uk

 

 

   

Media enquiries:

Abchurch Communications

 

Jamie Hooper / Alex Shaw

Tel: +44 (0) 20 7398 7719

quantumpharma@abchurch-group.com

www.abchurch-group.com

 

Notes to Editors

Quantum Pharma is a service-led, niche pharmaceutical manufacturer, developer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. Quantum Pharma operates through eight business units offering a portfolio of innovative and complementary products and services to primary and secondary care providers.

 

Quantum Pharmaceutical manufactures and supplies specials and special obtains for pharmacy chains, pharmaceutical wholesalers, hospitals and independent pharmacies in the UK.

 

Quantum Aseptic Services manufactures aseptically prepared sterile intravenous products, either individually for named patients or in batches.

 

UL Medicines sources and supplies unlicensed imported medicines and specials to hospitals, community pharmacies and wholesalers in the UK and overseas.

 

NuPharm offers product development, clinical trials product manufacture, and outsourced manufacture for solid and liquid dose batch-made specials and niche licensed medicines.

 

Biodose® a medicines delivery system that accommodates liquid and solid medication, supporting medicines administration and adherence for 50,000 patients, their carers and clinicians with Biodose Services® delivering pre-prepared medication regimes to care homes.

 

Colonis a product development business which takes niche pharmaceutical products through the regulatory pathway to achieve licensed and/or regulated status.

 

Lamda a full service contract development specialist with customers across Europe.

 

For further information, please visit www.quantumpharmagroup.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTDMGZLVGMGKZM

Related Shares:

Quantum Pharma
FTSE 100 Latest
Value9,548.87
Change65.29